This activity is consistent with routine option monetization and pre-scheduled trading plans. No signal of negative sentiment; monitor for additional sales outside this cluster.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $256.94entry
- T+1 · 9mo ago +0.32%α +1.23% · $257.75
- T+5 · 8mo ago −1.90%α −0.69% · $252.06
- T+20 · 8mo ago −14.38%α −6.44% · $220.00
- T+60 · 6mo ago −19.05%α −28.38% · $207.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ResMed CEO Michael J. Farrell exercised stock options and sold 4,991 shares in the open market for approximately $1.25 million. The transaction was part of a pre-arranged trading plan and not an outright purchase, with no cash outlay for the exercised shares.
Key Financial Metrics
Key Facts
- CEO Michael J. Farrell exercised 9,982 derivative securities in total (two tranches of 4,991 shares), one at $0 and one at $146.34 per share.
- Farrell sold 4,991 shares in the open market at $251.0322 per share, generating $1,252,901.71 in proceeds.
- The exercise at $0 suggests a cashless exercise or option swap, common in pre-arranged plans.
- Total open-market sale value: ~$1.25M, representing 0.0035% of ResMed’s $36.0B market cap, immaterial in scale.
Financial Impact
$1.25 million in open-market sales by CEO; no net buying, only exercise and partial sale
Risk Factors
- Perception risk if media mischaracterizes the sale as insider skepticism, though structure suggests planned execution.
- Concentration risk in executive ownership if further monetization continues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-RMD-1773232203311 |
Track record
19 reports on RMD
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +28.97% at T+60 after the Jun 1, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $234.11 Now $239.53 +2.32% settles Dec 9
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $229.94 Now $239.53 +4.17% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bearish 4/10 Entry $238.88 to $238.19 Now $239.53 −0.27% ▲ +0.29% −3.17% vs SPY
- Oct 7, 20265w ago 144 Neutral 3/10 Entry $226.73 to $240.51 Now $239.53 +5.65% ▲ +6.08% +11.37% vs SPY
- Oct 1, 20266w ago DEFA14A Neutral 2/10 Entry $218.89 to $229.94 Now $239.53 +9.43% ▲ +5.05% +6.86% vs SPY
- Oct 1, 20266w ago DEF 14A Neutral 4/10 Entry $218.89 to $252.83 Now $239.53 +9.43% ▲ +15.51% +17.31% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $218.89 Now $239.53 +9.43% No price data
- Sep 10, 20269w ago Insider Cluster Neutral 4/10 Entry $219.58 to $226.73 Now $239.53 +9.09% ▲ +3.26% +1.13% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $224.84 to $219.95 Now $239.53 +6.53% ▼ −2.17% −1.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers